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Abstract Phospholipase A2 (PLA2) constitutes a growing
superfamily of lipolytic enzymes, and to date, at least 19 distinct
enzymes have been found in mammals. This class of enzymes
has attracted considerable interest as a pharmacological target
in view of its role in lipid signaling and its involvement in a
variety of in£ammatory conditions. PLA2s hydrolyze the sn-2
ester bond of cellular phospholipids, producing a free fatty acid
and a lysophospholipid, both of which are lipid signaling mole-
cules. The free fatty acid produced is frequently arachidonic
acid (AA, 5,8,11,14-eicosatetraenoic acid), the precursor of
the eicosanoid family of potent in£ammatory mediators that
includes prostaglandins, thromboxanes, leukotrienes and lipox-
ins. Multiple PLA2 enzymes are active within and surrounding
the cell and these enzymes have distinct, but interconnected roles
in AA release.
+ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2) constitutes a superfamily of en-
zymes that catalyze the hydrolysis of the phospholipid sn-2
ester bond, generating a free fatty acid and a lysophospho-
lipid. The PLA2 reaction is the primary pathway through
which arachidonic acid (AA) is liberated from phospholipids.
Free AA is the precursor of the eicosanoids, which include the
prostaglandins, generated through the cyclooxygenase reac-
tion, and the leukotrienes, generated through the lipoxygenase
reaction [1]. Additionally, the PLA2 reaction generates a
platelet-activating factor (PAF) precursor when the lysophos-
pholipid product possesses a choline headgroup and an alkyl
linkage in the sn-1 position. In such instances, an acetyltrans-
ferase can act upon it to produce PAF (1-O-alkyl-2-acetyl-sn-
3-phosphocholine). Thus, PLA2 is an important signaling en-
zyme, through which multiple downstream e¡ectors are gen-
erated.
Eicosanoids and PAF are key mediators of in£ammation as
well as other pathophysiological conditions [1]. Because pros-
taglandins, leukotrienes and PAF may all be derived from the
action of a PLA2, direct inhibition of such an enzyme would
have the potential of blocking all three of the pathways at
once, which could be of therapeutic advantage in certain set-
tings. Thus, the pharmaceutical industry has pursued the de-
sign of drugs with potential anti-PLA2 e¡ects.
Targeting and inhibiting the PLA2 reaction has proved
problematic since numerous PLA2 enzymes have been identi-
¢ed with overlapping properties, including sites of expression
and inhibition susceptibility. In mammals, 19 proteins pos-
sessing PLA2 activity have been described (Tables 1 and 2),
all of which have been detected in humans, except for Group
IIC PLA2, which is encoded by a pseudogene [2]. Thus a ¢rst
step for a rational PLA2 drug design strategy should be to
de¢ne the di¡erent PLA2 classes present in cells and elucidate
the roles of the speci¢c enzymes in eicosanoid and PAF syn-
thesis.
2. PLA2 classi¢cation
PLA2s have been systematically classi¢ed on the basis of
their nucleotide and amino acid sequence [2^4]. The latest
update to this classi¢cation [2], published in October 2000,
included 11 groups, most of which also included several sub-
groups, but since the publication of that latest update, new
PLA2 enzymes have been described, leading to a 12th group
[5,6]. Tables 1 and 2 (adapted from Six and Dennis [2]) depict
the most current classi¢cation of the PLA2 enzymes. Group
XIII PLA2, identi¢ed in parvoviruses [7,8], and Group XIV
PLA2, identi¢ed in Symbiotic fungi [9] and Streptomyces
[10,11], have also now been added. Additionally, a putative
sea anemone PLA2 gene has recently been described [12]. Re-
markably, the cysteine residues of the primary structure of
this putative sea anemone PLA2 align perfectly with the mam-
malian Group V PLA2s; but, at this time, the sea anemone
protein does not meet the criteria for PLA2 classi¢cation as
previously delineated, i.e. PLA2 activity of the expressed pro-
tein has not been reported [2]. Very recently, a novel lysosom-
al Ca2þ-independent PLA2 has also been described. This en-
zyme also possesses 1-O-acylceramide synthase activity;
therefore, until the physiological activity of this enzyme is
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established or the speci¢c activity is quanti¢ed, classi¢cation
within the PLA2 system is premature [13].
A broader classi¢cation of the PLA2s that has historically
been utilized to describe PLA2 activities for which sequence
data are not available divides the PLA2 classes into three
types: secretory (sPLA2), cytosolic Ca2þ-dependent (cPLA2),
and cytosolic Ca2þ-independent (iPLA2). This classi¢cation
has numerous caveats, e.g. the Group IVC PLA2 is generally
referred to as cPLA2-Q, despite its being a Ca2þ-independent
enzyme. However, the system remains useful for making gen-
eralizations when describing properties of multiple PLA2
groups or when the speci¢c identity of a PLA2 is unknown.
3. PLA2 properties
With the expansion of the superfamily of PLA2 enzymes, it
has become increasingly di⁄cult to generalize the properties
of the PLA2s. However, in general, the mammalian sPLA2s
(Groups IB, IIA,C^F, III, V, X, XII) have low molecular
masses (13^19 kDa) and lack speci¢city for arachidonate-con-
taining phospholipids. The cPLA2s (Group IV, comprising
three subgroups) have higher molecular masses (s 60 kDa),
and preferentially hydrolyze arachidonate-containing phos-
pholipids (although Group IVC PLA2 exhibits only a margin-
al preference). Finally, the iPLA2s (Group VI) have high mo-
lecular masses (about 85 kDa) but are not selective for
arachidonate-containing phospholipids [2]. It is interesting to
note that the Ca2þ requirements of the PLA2s do not distrib-
ute within this classi¢cation system. For example, although
most of the sPLA2s require millimolar levels of Ca2þ for en-
zymatic activity, the recently described Group XII sPLA2 ap-
pears to be an exception, requiring WM Ca2þ levels. Second,
Group IVA and Group IVB require Ca2þ for translocation to
membranes but not for activity. However, Group IVC is an
exception, having no Ca2þ requirement, indicating some bio-
chemical commonality with the iPLA2s.
4. PLA2 and AA release
The functions of mammalian PLA2s have largely been
studied by examining the cellular regulation and activation
of the enzymes in response to speci¢c stimuli. Cellular re-
sponses to external stimuli via receptor-dependent or indepen-
dent pathways elicit a series of signals that ultimately lead to
Table 1
PLA2 groups utilizing a catalytic histidinea
Group Initial/common sources Size (kDa) Disul¢des
I A Cobra, krait venom 13^15 7
B Mammal pancreas 13^15 7
II A Human synovial £uid, platelets, rattlesnake, viper venom 13^15 7
B Gaboon viper venom 13^15 6
C Rat/mouse testis 15 8
D Human/mouse pancreas/spleen 14^15 7
E Human/mouse brain/heart/uterus 14^15 7
Fb Human/mouse testis/skin 16^17 7
IIIc Bee/lizard/scorpion/human 15^18 5
V Mammal heart/lung/macrophage 14 6
X Human spleen/thymus/leukocyte 14 8
IX Snail venom (Conodipine-M) 14 6
XI A Green rice shoots (PLA2-I) 12.4 6
B Green rice shoots (PLA2-II) 12.9 6
XII Mammal heart/kidney/skin, Muscle 18.7 7
XIII Parvovirus 6 10d 0
XIV Symbiotic fungus/Streptomyces 13^19 2
aThese are typically small extracellular PLA2s requiring Ca2þ for activity and possessing an active site histidine and aspartate pair. Table
adapted with permission from Six and Dennis [2].
bGroup IIF has an additional Cys in its C-terminal extension.
cHuman GIIIPLA2 (55 kDa) has additional novel C-terminal and N-terminal domains.
dThe parvovirus PLA2 motif encompasses only approximately 108 residues of the 81^89 kDa VP1up protein.
Table 2
PLA2 groups utilizing a catalytic serinea
Group Initial/common sources Alternate names employed Size (kDa) Ca2þ e¡ects
IV A Human U937 cells/platelets,
RAW 264.7/rat kidney
cPLA2K 85 6mM; membrane translocation
B Human pancreas/liver/heart/brain cPLA2L 114 6mM; membrane translocation
C Human heart/skeletal muscle cPLA2Q 61 None
VI A-1 P388D1 macrophages, CHO iPLA2 or iPLA2-A 84^85 None
A-2 Human B-lymphocytes, testis iPLA2-B 88^90 None
B Human heart/skeletal muscle iPLA2Q or iPLA2-2 88 None
VII A Human/mouse/porcine/bovine plasma PAF-AH 45 None
B Human/bovine liver/kidney PAF-AH (II) 40 None
VIII A Human brain PAF-AH Ib K1 (subunit of trimer) 26 None
B Human brain PAF-AH Ib K2 (subunit of trimer) 26 None
aLarger, typically intracellular enzymes that utilize a nucleophilic serine for hydrolytic cleavage with no disul¢de bonds and no Ca2þ require-
ment for catalysis. Table adapted with permission from Six and Dennis [2].
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altered PLA2 activity. Elucidation of primary and secondary
activating signals has been the subject of much e¡ort for the
last 10 years [14]. However, the complexity of the signaling
cascade and the identi¢cation of numerous mechanisms for
PLA2 activation are even further complicated by the overlap-
ping expression of multiple PLA2 enzymes within the cell. By
focusing on PLA2 responsiveness to macrophage activation,
our laboratory has developed a PLA2 signal transduction
model for P388D1 cells [15] (shown in Fig. 1).
The scheme shown in Fig. 1 has been generally con¢rmed
by many other laboratories [16] and thus can be regarded as a
currently accepted paradigm for PLA2 signaling in immunoin-
£ammatory cells. The macrophage-like cells generate either an
immediate response (induced by the Ca2þ-mobilizing agonist,
PAF) or a delayed response (induced by bacterial lipopolysac-
charide, LPS). PAF elicits the rapid activation of the PLA2
enzymes, whereas LPS primarily acts by inducing the cells to
synthesize new protein e¡ectors over the span of hours. In
both instances, the foremost event is the translocation and
activation of Group IVA PLA2 in an intracellular compart-
ment.
Group IVA (GIVA) PLA2 activation has been the subject
of many studies, and generally involves transient elevations of
the intracellular Ca2þ concentration and the action of the
mitogen-activated protein kinase (MAPK) cascade, resulting
in the phosphorylation of Ser505 within the catalytic domain
of GIVA PLA2 [17]. There are a few exceptions, however, in
which GIVA PLA2 activation has been described as being
activated in a Ca2þ-independent manner [18] and/or phos-
phorylated by kinases other than the MAPK family [19].
Following the activation of GIVA PLA2 is the activation of
an sPLA2, which, depending on cellular type, may belong to
Groups II, V, or perhaps other groups. Depending on the
stimulus, GIVA PLA2 modulation of sPLA2 cellular activity
may occur at the level of regulation of enzyme activity itself
(immediate responses) [15] or at the gene regulatory level (de-
layed responses) [20]. In the former case, a variety of cellular
mechanisms might account for this activation, including
GIVA PLA2-induced rearrangement of membrane phospho-
lipids, which in turn may result in the exposure of preferred
substrates to the Group II or V enzymes, or more sophisti-
cated biochemical mechanisms such as inactivation of endog-
enous sPLA2 inhibitors or Ca2þ £uxes. Unlike the Group II
and V PLA2s, Group X PLA2 does not require the prior
activation of GIVA PLA2 ; indeed, several groups have shown
that Group X PLA2 mediates spontaneous AA release from
the outer surface of the plasma membrane [21^23].
While it is clear that GIVA PLA2 acts on perinuclear mem-
branes, the precise site of action of sPLA2 has been the sub-
ject of numerous recent studies. The sPLA2 enzyme appears to
be released to the extracellular medium, and subsequently re-
associates with the outer cellular surface where it hydrolyzes
phospholipids. Recent studies have suggested that the enzyme
is re-internalized deep into the cell, probably via the caveolin
system to the vicinity of nuclear membranes [24]. Whether the
enzyme is still active in the cellular interior or whether inter-
nalization represents a signal termination mechanism is un-
clear at present [25]. Data in human neutrophils [26] and
mast cells [27] have suggested that sPLA2 internalization leads
to protein degradation. In stark contrast, however, in agonist-
induced human embryonic kidney (HEK) 293 cells [28,29]
internalization resulted in increased AA release and prosta-
glandin synthesis. The suggestion has been made that this
internalization process allows the sPLA2 to localize in the
vicinity of COX-2 in the nuclear envelope area, which would
ultimately result in a more e⁄cient conversion of AA into
prostaglandins [29].
The model depicted in Fig. 1 illustrates a scenario whereby
Fig. 1. Signal transduction mechanism in P388D1 macrophages. Group VIA PLA2 (iPLA2) regulates phospholipid reacylation, Group IVA
PLA2 (cPLA2) is activated by external stimuli and precedes the activation and/or secretion of Group V PLA2 (sPLA2). Adapted with permis-
sion from Balsinde and Dennis [15].
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the concerted action of two distinct PLA2s leads to a full AA
release response. GIVA PLA2 initiates the response and plays
primarily a regulatory role, whereas sPLA2 acts in a second
‘wave’ to amplify the response by providing a signi¢cant por-
tion of the total AA liberated, an intriguing ¢nding consider-
ing that sPLA2s are not arachidonyl-selective enzymes [30].
Needless to say, in those cellular systems that do not express
an sPLA2 or do so at very low levels [31], GIVA PLA2 would
be the only PLA2 enzyme responsible for the release.
In addition, sPLA2 may also act in a paracrine manner (i.e.
as a stimulus itself) on otherwise unstimulated cells near the
site where the sPLA2 enzyme was released. Under these set-
tings, sPLA2 has been shown to induce activation of GIVA
PLA2, thereby propagating the in£ammatory response to
neighboring cells [25]. Whether sPLA2 activity is actually re-
quired for GIVA PLA2 activation (i.e. whether or not sPLA2
acts on a speci¢c surface receptor) is a matter of debate and
probably depends on the type of cell that interacts with the
exogenous enzyme [30,32,33].
Studies on the involvement of Group VIA PLA2 (iPLA2) in
AA mobilization have largely been conducted by using bro-
moenol lactone, a compound that manifests high selectivity
for Group VIA PLA2 in vitro but whose selectivity in vivo
is unclear [34^36]. In phagocytic cells, bromoenol lactone has
no e¡ect on stimulus-induced AA mobilization, thus ruling
out a role for Group VIA PLA2 in the process [37^40]. In
contrast, in other cell types, most notably heart and pancre-
atic islets [41^43], bromoenol lactone potently suppresses
stimulus-induced AA release, which is consistent with the in-
volvement of Group VI PLA2.
Recently, Group VIA PLA2 has been shown to be respon-
sive to cellular stimuli including Ca2þ ionophore in HEK 293
cells [44] and glucose plus cAMP-elevating agents in INS-1
insulinoma cells [45], suggesting that the enzyme may play a
signaling role. These recent studies utilize cells overexpressing
Group VIA PLA2. Although these studies are useful for sug-
gesting enzymatic functions, the cells that overexpress an en-
zyme may not represent a true physiological responsiveness.
Therefore, additional cellular studies will be necessary to con-
¢rm if there is a signaling role for this enzyme.
In P388D1 macrophages [46] Group VIA iPLA2 is proposed
to mediate phospholipid reacylation reactions by regulating
the steady-state level of lysophosphatidylcoline. The lysophos-
pholipid acceptors produced by Group VIA PLA2 may be
used to re-incorporate part of the fatty acids (including AA)
that have previously been released by its Ca2þ-dependent
counterparts. Thus, by regulating AA reacylation reactions,
Group VIA PLA2 may participate in the formation of cellular
AA pools. Therefore an emerging model of PLA2 cellular
activity indicates that all three types of PLA2s (sPLA2,
cPLA2, iPLA2) appear to serve important but distinct func-
tions regarding AA mobilization in cells.
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